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Introduction
Cdk1 and its associated protein cyclin B1 are required for entry 
into and maintenance of the mitotic state in mammalian cells 
(Evans et al., 1983; Minshull et al., 1989; Nurse, 1990). Exit 
from mitosis in mammalian cells requires the inactivation of 
Cdk1, the protein kinase that drives the mitotic state (Murray, 
2004). Inactivation follows the destruction of the Cdk1-activating 
subunit cyclin B1 by proteolysis (Murray et al., 1989; Hershko 
et al., 1991; Holloway et al., 1993), a process normally acti-
vated at metaphase by anaphase-promoting complex/cyclosome 
(APC/C)–driven ubiquitination (Glotzer et al., 1991; Hershko 
et al., 1991). Failure to degrade cyclin B1 results in constitutively 
active Cdk1 and indefi  nite arrest in mitosis (Murray et al., 1989; 
Ghiara et al., 1991; Gallant and Nigg, 1992; Holloway et al., 
1993). As Cdk1 inactivation is not required for progression past 
metaphase, vertebrate cells and in vitro cell model systems can 
arrest either in metaphase or in later stages of mitosis in the 
presence of constitutively active Cdk1 (Holloway et al., 1993; 
Wheatley et al., 1997; Stemmann et al., 2001).
Inactivation of Cdk1 itself has been considered to be neces-
sary and suffi  cient to induce a rapid exit from mitosis. Exposure 
of cells to specifi  c inhibitors of Cdk1 causes rapid mitotic exit 
(Potapova et al., 2006). The APC/C E3 ubiquitin protein ligase 
processively ubiquitinates specifi  c sequence tags (Rape et al., 
2006), principally D-box (Glotzer et al., 1991) or KEN-box 
(Pfl  eger and Kirschner, 2000) motifs, in multiple target proteins 
in the course of mitotic exit (Peters, 2002) and targets them for 
proteasome destruction. The degradation of two proteins, cyclin 
B1 and securin, is linked to proper mitotic exit. Destruction of 
  cyclin B1 is absolutely necessary for mitotic exit (Gallant and Nigg, 
1992; Holloway et al., 1993). Although the destruction of securin 
is required for proper chromosome segregation, failure to destroy 
securin does not block mitotic exit (Zur and Brandeis, 2001).
In this study, we analyze the state of cells exposed to Cdk1 
inhibitors in combination with the suppression of proteolysis 
and present evidence that the mitotic state (defi  ned as the con-
tinuous presence of condensed chromosomes) of a mitotic spindle 
and of mitotic phosphoprotein antigens is sustained for a long 
period in the absence of Cdk1 activity, but only when APC/C-
dependent protein degradation is simultaneously suppressed.
We fi nd that the capacity to sustain mitotic status corre-
lates with the persistence of phosphorylated Cdk1 substrates in 
the absence of Cdk1 activity. Thus, our results demonstrate that 
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ellular transition to anaphase and mitotic exit has 
been linked to the loss of cyclin-dependent kinase 1 
(Cdk1) kinase activity as a result of anaphase-
promoting complex/cyclosome (APC/C)–dependent spe-
ciﬁ  c degradation of its cyclin B1 subunit. Cdk1 inhibition 
by roscovitine is known to induce premature mitotic exit, 
whereas inhibition of the APC/C-dependent degradation 
of cyclin B1 by MG132 induces mitotic arrest. In this study, 
we ﬁ  nd that combining both drugs causes prolonged 
mitotic arrest in the absence of Cdk1 activity. Different 
Cdk1 and proteasome inhibitors produce similar results, 
indicating that the effect is not drug speciﬁ  c. We verify 
mitotic status by the retention of mitosis-speciﬁ  c markers 
and Cdk1 phosphorylation substrates, although cells can 
undergo late mitotic furrowing while still in mitosis. Overall, 
we conclude that continuous Cdk1 activity is not essential 
to maintain the mitotic state and that phosphatase activity 
directed at Cdk1 substrates is largely quiescent during 
mitosis. Furthermore, the degradation of a protein other 
than cyclin B1 is essential to activate a phosphatase that, 
in turn, enables mitotic exit.
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Figure 1.  Loss of Cdk1 kinase activity in the absence of proteasome activity does not lead to mitotic exit. (A) Mitotic HeLa cells were collected by selective 
detachment after being blocked in mitosis with 7.5 μM STLC (left) or with 0.1 μg/ml nocodazole (right) for 16 h. Cells in the continuous presence of the mi-
totic inhibitors were exposed to 100 μM roscovitine (ROS) or 20 μM MG132 or to both roscovitine and MG132, and samples for 2D FACScan analysis 
were taken 2 h after drug addition. In contrast to roscovitine treatment, cells in the presence of MG132 retained their mitotic state, as indicated by MPM2 
signal. Similarly, the majority of cells coincubated with roscovitine and MG132 remained mitotic. The percentages shown indicate the cell subpopulation MITOSIS WITHOUT CDK1 ACTIVITY • SKOUFIAS ET AL. 673
Cdk1 inactivation alone is not suffi  cient to induce mitotic exit. 
Instead, key serine/threonine protein phosphatases, which are 
required for mitotic exit, are largely inactive during mitosis and 
must be reactivated by a proteolytic event so that they, in turn, 
can dephosphorylate Cdk1 substrates and enable mitotic exit. 
Our results show an unexpected convergence of the mammalian 
system with yeast in which phosphatase activity is required for 
mitotic exit (Stegmeier and Amon, 2004).
Results
Sustained mitosis in cells when both Cdk1 
activity and proteolysis are suppressed
HeLa cells were collected in mitosis by exposure to S-trityl-l-
cysteine (STLC), a potent and specifi  c inhibitor of the microtubule 
motor protein Eg5 (Skoufi  as et al., 2006), or to noco  dazole, an 
inhibitor of microtubule assembly (Zieve et al., 1980). We then 
tested the effect of cell exposure to the specifi  c Cdk1 inhibitor 
roscovitine or to the protease inhibitor MG132. The mitotic 
state was determined by fl  ow cytometric assay of the presence 
of MPM-2, a well-established mitosis-specifi  c phosphoprotein 
substrate and mitotic marker (Davis et al., 1983; Andreassen 
and Margolis, 1994). As previously demonstrated (Payton et al., 
2006; Vassilev et al., 2006), exposure to Cdk inhibitors such as 
roscovitine for 2 h induced rapid mitotic exit (Fig. 1, A and B). 
On the other hand, exposure to MG132 sustained the mitotic 
state (Brito and Rieder, 2006).
We then tested the effect of exposing HeLa cells to the 
combination of roscovitine and MG132. Importantly, the pres-
ence of MG132 substantially prevented roscovitine-treated cells 
from losing MPM-2 phosphoproteins despite the absence of 
Cdk1 activity (Fig. 1). The retention of MPM-2 phosphopro-
teins provides evidence for continued mitotic status in the com-
bined presence of roscovitine and MG132. Quantitation of fl  ow 
cytometric data over a time course demonstrated that the per-
centage of mitotic cells exposed to both drugs initially dimin-
ished but then remained stable at  60% of the time 0 value 
(Fig. 1 B). The difference from the fate of cells exposed to 
roscovitine alone was striking. Essentially, no cells remained 
mitotic after 60 or 90 min of exposure to roscovitine in the con-
tinued presence of STLC or of nocodazole (Fig. 1 B).
Continued mitotic status, which is represented by the re-
tention of MPM-2 phosphoantigen, was supported by the reten-
tion of phosphorylated histone H3. Histone H3 is phosphorylated 
on S10 during mitosis by Aurora kinase (Hsu et al., 2000; Giet 
and Glover, 2001; Crosio et al., 2002), and phosphorylated H3 
has been used as a specifi  c mitotic marker (Hendzel et al., 1997). 
Western blots showed that phosphorylated H3 was absent after 
2 h of roscovitine exposure but was retained in the combined 
presence of roscovitine and MG132 (Fig. 1 C, (PS10)H3). 
  Aurora A, securin, and cyclin B1, proteins normally degraded 
on mitotic exit (Peters, 2002), were largely absent after 2 h of 
roscovitine treatment but were retained in cells exposed to the 
combination of roscovitine and MG132 (Fig. 1 C).
We obtained similar results after the exposure of cells to 
two other Cdk inhibitors, CGP74514A and purvalanol A. First, 
we conducted dose-response experiments to determine the mini-
mum concentration of inhibitors capable of inducing the com-
plete mitotic exit of nocodazole-arrested cells (unpublished 
data). Then, mitotic cells were exposed to the Cdk inhibitors in 
the presence of MG132. Results were comparable with those 
with roscovitine. Neither 7.5 μM CGP74514A nor 25 μM purv-
alanol A were able to drive mitotic exit in the presence of MG132 
(Fig. 2 A). Furthermore, we also assayed the effect of substitut-
ing MG132 with another proteasome inhibitor, AM114, and 
  obtained similar retention of the mitotic status in the absence 
of Cdk activity (Fig. 2 B). Western blot analysis of the extracts 
from treated cells showed similar patterns of the phosphory-
lation of Cdk substrates and of phosphorylated H3, Aurora A, and 
cdc27 (Fig. 2 C). Chromosome spreads confi  rmed the mitotic 
status of cells treated either with CGP74514A + MG132 or 
with CGP74514A + AM114 (Fig. 2 D). The different combina-
tions of inhibitors of Cdk and proteasome argue against the pos-
sibility that our results are artifactually caused by MG132 
specifi  cally dampening the inhibitory activity of roscovitine. 
Additionally, we extended our 2D FACScan analysis to another 
human cell line, HCT116, and the results were qualitatively and 
quantitatively similar: compared with nocodazole-blocked cells, 
85% of cells incubated with AM114 + roscovitine were MPM2 
positive (unpublished data). Importantly, a nontransformed   human 
cell line, IMR90, also remained substantially mitotic on exposure 
to combinations of either MG132 + roscovitine in the presence 
of nocodazole, AM114 + roscovitine, or AM114 + CGP74514A 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb
.200704117/DC1). We conclude that nontransformed cells remain 
fully mitotic in different conditions of Cdk1 inhibition, a result 
comparable to that with transformed cells.
Immunofl  uorescence microscopy confi  rmed mitotic sta-
tus in HeLa lacking Cdk1 activity. Fig. 3 A shows images with 
roscovitine + MG132. As expected, MG132 prevented the 
destruction of proteins normally degraded during mitotic exit. 
On continuous exposure to the Eg5 inhibitor STLC, control cells 
contained condensed chromosomes and a single aster spindle 
(tubulin label). The chromosomes were positive for the mitotic 
markers phosphohistone H3 and MPM-2. Lamin B, a marker 
for interphase nuclear envelopes, was dispersed, as is normal 
during mitosis (Gerace and Blobel, 1980). In contrast, cells 
treated with roscovitine for 2 h in the presence of STLC exited 
that was positive for MPM-2. (B) Quantitation of the percentage of cells positive for MPM-2 calculated relative to the mitotic value of cells at time 0, which 
was deﬁ  ned as the time of shake-off and addition of the various drug combinations. (C) Immunoblot analysis of various mitotic markers assayed at 2 h after 
shake-off of mitotic cells and addition of various drug combinations. Mitotic exit induced by roscovitine leads to the degradation of Aurora A, cyclin B1, 
and securin as well as loss of the mitosis-speciﬁ  c phosphorylation of residue S10 of H3 ((PS10)H3). In contrast, the addition of MG132, even in the pres-
ence of roscovitine, leads to stabilization of all of the proteins tested as well as retention of the phosphorylated status of H3. Release in medium alone (DME) 
served as a mitotic exit control.JCB • VOLUME 179 • NUMBER 4 • 2007  674
Figure 2.  Absence of mitotic exit after loss of Cdk1 kinase activity is independent of speciﬁ  c drugs. (A) Mitotic HeLa cells were collected by selective detach-
ment after being blocked in mitosis with 0.1 μg/ml nocodazole for 16 h. Cells in the continuous presence of nocodazole were exposed to 20 μM MG132 
(MG) for 1 h before the addition of Cdk inhibitors roscovitine (ROS; 100 μM) or CGP74514A (CGP; 7.5 μM), or cells were exposed to 25 μM purvalanol A 
(PURVA) for 2 h in the continuous presence of MG132. Samples for 2D FACScan analysis were taken after drug addition to determine DNA and MPM-2 
content (as in Fig. 1). The percentage of 4N cells positive for MPM-2 was quantitated from FACScan and plotted relative to the mitotic value of cells at time 0, 
which was deﬁ  ned as the time of shake-off and addition of the various drug combinations. In contrast to Cdk inhibitor treatments, cells in the presence of 
MG132 retained their mitotic state, as indicated by MPM2 signal. Similarly, the majority of cells coincubated with Cdk inhibitors and MG132 remained 
  mitotic. Error bars represent SD. (B) Cells were treated and analyzed as in A, but MG132 was substituted with 20 μM of the proteasome inhibitor AM114. 
Quantitation of the percentage of 4N cells positive for MPM-2 was calculated as in A. (C) Immunoblot analysis of various mitotic markers assayed at 2 h after 
shake-off of mitotic cells and addition of various drug combinations. Mitotic exit induced by Cdk inhibitors leads to loss of the mitosis-speciﬁ  c phosphorylation 
of Cdk substrates as well as the following mitotic markers: residue S10 of H3 ((PS10)H3) and residue T244 of cdc27. In contrast, the addition of MG132, 
even in the presence of Cdk inhibitors, leads to retention of the phosphorylated status of the proteins. Similar results were obtained for purvalanol A in place 
of roscovitine or CGP74514A and AM114 in place of MG132 (not depicted). (D) Chromosome spreads of representative cells in CGP74514A + MG132 
or CGP74514A + AM114 show mitotic status. Results compared with MG132 or AM114 alone. DNA stain is propidium iodide. Bar, 13 μm.MITOSIS WITHOUT CDK1 ACTIVITY • SKOUFIAS ET AL. 675
Figure 3.  Loss of Cdk1 activity in the absence of proteasome activity does not lead to mitotic exit. (A) After STLC treatment and mitotic shake-off, cells were 
treated with roscovitine in the absence or presence of MG132 for 2 h. Fixed cells were then stained for immunoﬂ  uorescence microscopy with antitubulin, 
phosphorylated histone H3 ((PS10)H3), MPM-2, or anti–lamin B antibodies (green) and were counterstained with propidium iodide (PI; red). Roscovitine in-
duced rapid mitotic exit, as evidenced by loss of the monoastral spindles, (PS10)H3, MPM-2 staining, and the assembly of nuclear lamina surrounding de-
condensed chromatin. However, cells treated with STLC plus roscovitine and MG132 retained monoastral spindles, (PS10)H3, and MPM-2 staining, whereas 
nuclear lamina were absent. These results were parallel to control cells blocked in mitosis with STLC. Microscope settings were held constant for all image ac-
quisitions. (B and C) The percentage of cells with monoastral spindles (B) or positive for (PS10)H3 (C) were quantitated. The data represent the mean of three 
counts of >60 cells per count. Gray bar, cells at time 0, the time of mitotic cell selection by shake-off; white bars, cells treated with roscovitine alone; black 
bars, cells treated with roscovitine plus MG132. In all cases, cells were in the continuous presence of STLC. Error bars represent SD. Bar, 16.5 μm.
mitosis and, thus, lost condensed chromosomes, the monoastral 
spindle, histone H3 phosphorylation, and the MPM-2 phospho-
antigen but had gained a lamin nuclear border (Fig. 3 A). These 
controls showed the status of markers in continued mitotic ar-
rest or in mitotic exit. On exposure to the combination of rosco-
vitine + MG132, cells appeared like the mitotic cells blocked in JCB • VOLUME 179 • NUMBER 4 • 2007  676
STLC and showed no sign of mitotic exit by any criterion de-
spite the absence of Cdk1 activity. All Cdk and proteasome 
  inhibitor combinations yielded similar images with respect to 
mitotic exit (unpublished data).
We quantitated the percentage of the mitotic population 
that retained two mitotic markers, monoastral spindles or S10 
phosphorylated histone H3, during 2 h of exposure to either 
roscovitine alone or to the combination of roscovitine and 
MG132 (Fig. 3 B). For this purpose, cells were fi  rst collected by 
mitotic shake-off after block in STLC, which yielded  80% 
mitotic cells that were positive for each of the two markers at 
time 0 (Fig. 3 B). By 1 h, roscovitine exposure resulted in al-
most a complete loss of monoastral spindles or phosphorylated H3. 
In contrast, cells exposed to the combination of roscovitine and 
MG132 almost completely retained these markers compared 
with time 0. Similar results were obtained with antiphospho-S10 
histone H3 (Fig. 3 C). Other Cdk and proteasome inhibitors 
yielded similar data (unpublished data).
To exclude the possibility that our results were caused by 
artifactual interference of the proteasome inhibitor with suppres-
sion of Cdk1 activity by Cdk1 inhibitors, we conducted an in vitro 
assay of Cdk1 histone H1 phosphorylation activity in the pres-
ence of purvalanol A or roscovitine alone, or of Cdk1 histone H1 
phosphorylation activity in the combined presence of purvalanol 
A + MG132 or roscovitine + MG132. The result (Fig. 4) clearly 
showed that both purvalanol A and roscovitine substantially sup-
pressed Cdk1 activity and that the further addition of MG132 did 
not interfere with Cdk1 inhibition. All drugs were assayed in vitro 
at the same concentrations that were effective in cells.
Nondegradable cyclin B1 and securin do 
not prevent mitotic exit in the absence of 
Cdk1 activity
The prevention of mitotic exit using the combination of ros-
covitine, purvalanol, or CGP74514A with either MG132 or 
AM114 suggests that the suppression of degradation of a key 
protein protects the cell from mitotic exit in the absence of Cdk1 
activity. To confi  rm that retention of mitotic status was not 
  dictated by the continued presence of cyclin B1 or securin, we 
assayed the effect of retention of these two proteins, whose deg-
radation is known to be essential for proper mitotic exit. For this 
assay, we expressed nondegradable mutants (cyclin B1 R4A2 
and securin KEN DM [destruction box mutant]) of the two pro-
teins using either single- or double-transfection protocols. 
Transfection with cyclin B R4A2 showed that the presence of 
nondegradable cyclin B was not suffi  cient to maintain mitosis 
because in the presence of roscovitine, expressing cells were 
negative for MPM-2, as was the case in nontransfected controls 
(Fig. 5 A). In contrast, transfected (GFP-positive cells) and non-
transfected cells both remained positive for MPM-2 in the pres-
ence of roscovitine + MG132 after 2 h (Fig. 5 A).
After double transfection, cells retained their mitotic sta-
tus in the presence of MG132 + roscovitine, as indicated by 
Western blot analysis of the mitotic-specifi  c phosphorylation of 
Cdk substrates as well as by the presence of mitosis-specifi  c 
markers, phosphorylated H3 and cdc27 (Fig. 5 B). We found 
that neither cyclin B1 R4A2 nor securin KEN DM was degraded 
on exposure of mitotic cells to roscovitine (Fig. 5 B). Nonethe-
less, cells rapidly exited mitosis, as assayed by the loss of S10 
phosphohistone H3, PT244cdc27, and Cdk phosphosubstrates. 
As before, the combination of roscovitine and MG132 prevented 
mitotic exit. Endogenous cyclin B1 and securin acted as internal 
controls in these experiments and degraded during mitotic exit 
in the presence of roscovitine (Fig. 5 B). Similar Western blot 
results were obtained after single transfection with either cyclin 
B1 R4A2 or securin KEN DM alone (unpublished data).
Late mitotic events in the absence of Cdk1 
and proteasome activity
The combined presence of a Cdk1 inhibitor and a protease in-
hibitor induced mitotic cells to proceed to cell cleavage (Potapova 
et al., 2006). We have carefully observed the status of cells 
blocked by a combination of roscovitine and MG132, and we 
have found the initiation of monoastral furrowing in a substan-
tial subpopulation of cells. This furrowing event was essentially 
the same as that previously observed in cells treated with mon-
astrol (another inhibitor of Eg5) and forced to exit mitosis by 
suppression of the spindle assembly checkpoint (Canman et al., 
2003). Indeed, cells frequently formed what we interpreted as a 
bud, creating a small daughter cell that contained no chromatin 
(Fig. 6 A). Such bud formation occurred with approximately 
equal frequency in cells treated with roscovitine alone or with 
the combination of roscovitine and MG132. The difference in 
outcome was that treatment with roscovitine alone caused the 
loss of mitotic chromosomes, whereas budded cells treated with 
both roscovitine and MG132 retained mitotic chromosomes.
The budding was a true furrowing event, as the passenger 
proteins survivin (Skoufi  as et al., 2000), Aurora B (Adams et al., 
2000), and TD60 (Mollinari et al., 2003) relocalized to the 
neck of the bud both in cells treated with roscovitine alone or 
with the combination of roscovitine and MG132 (Fig. 6 B). 
Furthermore, PRC1 and anillin, two proteins that localize to the 
furrow and are critical to cell cleavage (Jiang et al., 1998; 
Oegema et al., 2000; Mollinari et al., 2002, 2003), were also 
present at the bud necks (Fig. 6 B). The percentage of cells that 
Figure 4.  Cdk1 inhibition by purvalanol A and roscovitine but not MG132. 
Immunoprecipitates pulled down with Cdk1 antibody from nocodazole-
  arrested HeLa cell lysates were used for in vitro kinase assays. (top) 25 μM 
purvalanol A or 100 μM roscovitine or the combination of purvalanol A 
or roscovitine with MG132 was added to the kinase assay cocktail 
and incubated with the immunoprecipitates for 30 min at 30°C in the 
presence of [
32P]ATP. (bottom) Immunoblot of Cdk1 immunoprecipitates 
( 10% input) cross-blotted using anti-Cdk1 antibody to demonstrate equal 
lane loading.MITOSIS WITHOUT CDK1 ACTIVITY • SKOUFIAS ET AL. 677
exhibited budding is summarized (Fig. 6 C). We interpret these 
results as indicating that furrowing occurs in the absence of 
Cdk1 activity and in the absence of proteolysis. However, such 
furrowing occurs in the absence of mitotic exit.
Because monoastral cells proceeded to furrow in the pres-
ence of roscovitine and MG132, we next addressed the fate of 
cells released from STLC block in the presence of roscovitine 
and MG132. The question was whether cells without Cdk1 
Figure 5.  Degradation of cyclin B1 and securin is not necessary for mitotic exit in the absence of Cdk1 activity. (A and B) HeLa cells were transiently trans-
fected with cDNA coding nondegradable cyclin B1 (R4A2GFP) alone (A) or both cDNA coding nondegradable cyclin B1 (R4A2GFP) and nondegradable 
securin (KEN-box mutant myc-securin-KAA-DM; B). At 30 h after transfection, cells were synchronized in mitosis by 16-h exposure to nocodazole. After 
shake-off, mitotic cells were maintained in the continuous presence of nocodazole with either roscovitine (ROS), MG132, or both roscovitine + MG132. 
(A) Immunoﬂ  uorescence shows that nondegradable cyclin B is not sufﬁ  cient to maintain mitotic status in the presence of roscovitine because GFP-positive 
cells are negative for MPM-2 staining. Both GFP-positive and -negative cells are MPM-2 positive after mitotic shake-off in MG132 and in roscovitine + 
MG132. (B) Immunoblot analysis of cellular extracts from double-transfected cells shows that in the presence of roscovitine, endogenous cyclin B1 and 
  securin were degraded, whereas the ectopically expressed nondegradable proteins were not. Despite the continued presence of cyclin B or securin, exposure 
to roscovitine induced mitotic exit followed by the loss of (PS10)H3, (PT244)cdc27, and Cdk phosphoprotein substrates. In contrast, in cells treated with 
MG132 alone or with MG132 plus roscovitine, there was no loss of these markers, conﬁ  rming the continued mitotic status of these cells. Bar, 44.5 μm.JCB • VOLUME 179 • NUMBER 4 • 2007  678
  activity would proceed through the normal stages of mitosis or 
would proceed directly to furrowing in the absence of Cdk1 ac-
tivity. For this experiment, HeLa mitotic cells were collected by 
shake-off after 18 h of block in STLC and were released from 
STLC in the presence of MG132 alone or roscovitine + MG132. 
When cells were released without further treatment, <17% 
  remained mitotic at 4 h as determined by FACScan analysis 
(Fig. 7 A). In contrast, release into MG132 for 2 h yielded 68% 
in mitosis compared with 73.5% in the initial mitotic popula-
tion. The same result was obtained when cells were released 
into MG132 for 2 h and treated with a combination of roscovi-
tine and MG132 for a further 2 h. Despite the absence of Cdk1 
Figure 6.  Cells with monoastral spindles cleave without mitotic exit after loss of Cdk1 activity in the presence of proteasome inhibitor. (A and B) HeLa cells 
collected in mitosis by 16-h exposure to STLC followed by mitotic shake-off were maintained in STLC and treated with roscovitine in the presence or absence 
of MG132 for 2 h. Cells were then ﬁ  xed and stained for microscopy with antibodies to tubulin (A) or to the cleavage furrow–associated proteins survivin, 
Aurora B, TD60, PRC1, or anillin (B). Exposure of STLC-treated cells to roscovitine induced a furrowing event, characteristically with formation of a bud de-
void of chromatin. The passenger proteins survivin, Aurora B, and TD60 associated with the furrow, as did PRC1 and anillin. (C) The percentage of cells 
with a bud was quantitated after 1 or 2 h of exposure to drugs. The data represent the mean of three counts of >60 cells per count. White bars, cells 
treated with roscovitine; black bars, cells treated with both roscovitine and MG132. All cells were in the continuous presence of STLC. Error bars represent SD. 
Bar, 16.5 μm.MITOSIS WITHOUT CDK1 ACTIVITY • SKOUFIAS ET AL. 679
activity, there was no further loss of mitotic population (66.2% at 
4 h). Observed by immunofl  uorescence microscopy, the popula-
tion of cells treated with the combination of roscovitine and 
MG132 was largely prometaphase (bipolar spindles with most 
chromosomes aligned to the metaphase plate but with a few chro-
mosomes misaligned) or metaphase (bipolar spindles with all 
chromosomes aligned to the metaphase plate), as shown in Fig. 
7 B. Thus, the absence of Cdk1 activity did not prevent cells from 
maintaining a bipolar spindle and a metaphase chromosome array. 
Furthermore, no cells treated in this manner proceeded to furrow 
in this time frame, but all remained in early mitosis in the absence 
of Cdk1 activity (Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200704117/DC1). It is of interest to note that co-
incubation with roscovitine and MG132 caused the reproducible 
loss of metaphase cells by reversion to prometaphase (Fig. S2 A).
We conducted a parallel analysis of cells after release 
from STLC into MG132 followed by exposure to Cdk1 inhibi-
tor CGP74514A. Immunofl  uorescence yielded metaphase mi-
totic images similar to those seen with roscovitine (Fig. S2 B). 
As with roscovitine + MG132, coexposure of CGP74514A 
with MG132 yielded largely bipolar spindles, but with a small 
increase in monopolar cells (Fig. S2 C). These data suggest that 
Figure 7.  The absence of Cdk1 activity does not prevent bipolar spindle formation and metaphase chromosome alignment on release from STLC. (A) After 
16-h STLC block and mitotic shake-off, cells were released from STLC by three washes in drug-free medium and were treated with MG132 for 2 h followed 
by 2-h coincubation with both roscovitine and MG132. Samples were analyzed by 2D FACScan as in Fig 1. Controls were released from STLC for 4 h 
with no further drug treatment. Percentages shown indicate the subpopulations that were positive for MPM-2. (B) Confocal microscopy was performed on 
identically treated cells, which were stained for tubulin (green) and DNA with propidium iodide (PI; red). The combined FACScan and microscopy data in-
dicate that controls released from STLC form normal bipolar spindles and exit normally from mitosis. In contrast, cells released from STLC in MG132 remain 
mitotic but within 2 h have normal mitotic spindles with chromosomes aligned to a normal metaphase plate. After an additional 2 h without Cdk1 activity 
(MG132 plus roscovitine), cells remained mitotic with normal bipolar spindles and metaphase chromosome alignment. Bar, 16.5 μm.JCB • VOLUME 179 • NUMBER 4 • 2007  680
Figure 8.  Phosphatase activity is required for mitotic exit in the absence of Cdk1 activity. (A) Western blot analysis of mitotic markers in extracts. Cells were 
collected in mitosis by STLC block (16 h) and shake-off and were exposed to different conditions for 2 h as indicated. All cells were maintained in STLC during 
this time course. Cells were exposed to 100 μM roscovitine (ROS), 20 μM MG132, both roscovitine and MG132, both roscovitine and 0.5 μM okadaic 
acid (OKAD), or to both roscovitine and 30 nM calyculin A (CALYC). Controls were cells in the continuous presence of STLC (2 h) or STLC + MG132 
(MG132). S/O indicates the time 0 shake-off sample. Cell extracts were probed with a polyclonal antibody speciﬁ  c for Cdk substrates phosphorylated on MITOSIS WITHOUT CDK1 ACTIVITY • SKOUFIAS ET AL. 681
continued Cdk1 activity may be required to maintain the meta-
phase alignment of chromosomes.
Phosphorylation status of most Cdk1 
substrates is retained when both Cdk1 
and proteasome activities are inhibited
Maintenance of the mitotic state in the absence of Cdk1 activity 
might depend on the retention of phosphorylated Cdk1 sub-
strates during combined Cdk1 suppression + MG132 treat-
ment. In Fig. 2 C, using an antibody specifi  c for Cdk1 substrate 
consensus motif phosphopeptides, we showed that the phos-
phorylation status of Cdk1 substrates (Stukenberg et al., 1997) 
was indeed retained in cells exposed to the combination of 
roscovitine  + MG132 or CGP74514A + MG132. Western 
blots showed that mitotic cells were highly positive for a large 
number of Cdk1 phosphoepitopes and that these substrates were 
absent after 2 h of Cdk1 inhibitor exposure (Fig. 2 C).
These results suggested that protein phosphatases were 
not acting on Cdk1 substrates in the absence of Cdk1 activity. 
As this offered a possible mechanism for sustained mitotic status 
without Cdk1, we directly assayed for the effect of phosphatase 
inhibition in cells treated with roscovitine and found that the 
dephosphorylation of Cdk1 substrates was indeed suppressed 
in mitotic cells exposed to the combination of roscovitine plus 
either okadaic acid or calyculin A (Fig. 8 A), two specifi  c in-
hibitors of PP1 and PP2A protein phosphatases (Bialojan and 
Takai, 1988; Ishihara et al., 1989; Cohen et al., 1990). These 
results correlated with FACScan data showing retention of the 
mitotic marker MPM-2 in STLC-treated cells (Fig. 8 B). Re-
sults quantitated for cells collected in mitosis either with STLC 
or with nocodazole (Fig. 8 C) show substantial mitotic reten-
tion with roscovitine + either okadaic acid or calyculin A. 
In comparison, the inhibition of cdc25, a mitotic protein phos-
phatase (for review see Trinkle-Mulcahy and Lamond, 2006), 
was without effect on mitotic exit of roscovitine-treated cells, 
nor did its suppression protect cells from the dephosphoryla-
tion of Cdk1 substrates (Fig. S3, available at http://www.jcb
.org/cgi/content/full/jcb.200704117/DC1).
Chromosome spreads of cells treated with Rosc + either 
okadaic acid or calyculin A showed that condensed mitotic chro-
mosomes were maintained at high levels with the combined sup-
pression of Cdk1 and phosphatase activity (Fig. S4, available 
at http://www.jcb.org/cgi/content/full/jcb.200704117/DC1). 
Representative chromosome spreads are shown in Fig. 8 D.
Condensed chromosomes were equivalently maintained 
with either MG132 alone or Rosc + MG132 but unlike roscovi-
tine alone, in which the majority of cells had reformed nuclei by 
2 h (Fig. S4). Interestingly, mitotic arrest with Rosc + either 
okadaic acid or calyculin A occurred despite the loss of cyclin 
B1 and securin by 2 h (Fig. 8 A). Thus, phosphatase activity did 
not appear to be required for activation of cyclin B1 or securin 
degradation by APC/C-linked proteolysis.
We conclude that phosphatase activity, possibly involving 
either PP1 or PP2A, is an essential prerequisite for mitotic exit 
after Cdk1 inactivation. Furthermore, our data suggest that MG132-
sensitive proteolysis of a proteasome substrate other than cyclin 
B1 is required to activate this phosphatase activity.
Discussion
Maintenance of the mitotic state depends on Cdk1 activity. Loss of 
Cdk1 activity normally occurs at the metaphase to anaphase tran-
sition once the spindle assembly checkpoint and other mitotic 
checkpoints have been satisfi  ed (Kops et al., 2005). Mitotic exit 
normally occurs through the cdc20-activated APC/C-dependent 
degradation of two key substrates, cyclin B1 and securin.
We have demonstrated that mitotic cells will remain mi-
totic for several hours in the absence of Cdk1 activity provided 
that APC/C-dependent protease activity is suppressed. Contin-
ued mitotic status in the absence of Cdk1 activity has been veri-
fi  ed by several independent criteria: the continued presence of 
condensed chromosomes, the presence of a mitotic spindle, the 
presence of the mitosis-specifi  c phosphoantigen markers MPM-2 
and S10 of histone H3, and the presence on chromosomes of 
mitotic passenger proteins. Finally, and most importantly, we 
show that Cdk1 substrates remain phosphorylated in the absence 
of Cdk1 activity.
Thus, our results require a revision of the prevailing para-
digm, which holds that destruction of cyclin B1, which inacti-
vates Cdk1, is itself necessary and suffi  cient to induce mitotic 
exit. This paradigm requires that suppression of Cdk1 activity 
should therefore induce mitotic exit even in the absence of 
  cyclin B1 destruction. Instead, our results show there is a path-
way downstream of Cdk1 inactivation that requires both fur-
ther proteolysis and phosphatase activation to complete the 
mitotic exit pathway.
Our results contrast with a recent study that proposed that 
cells exposed to both a Cdk1 inhibitor and an inhibitor of prote-
olysis undergo cell cleavage but remain competent to revert to 
mitosis when the Cdk1 inhibitor is removed (Potapova et al., 
2006). The interpretation of these results as evidence for a re-
versible exit from mitosis dependent on the continued presence 
of cyclin B1 rested on the reversibility of cell cleavage and the 
reappearance of a rounded mitotic cell. Other markers that 
serine (anti P-Ser Cdk substrates), with antibody speciﬁ  c for histone H3 phosphorylated on Ser10 ((PS10)H3), and were also probed with securin, cyclin B1, 
and aurora A antibodies. Anti-actin was used as loading control. (B) FACScan analysis of mitotic HeLa cells collected by shake-off after being blocked in mito-
sis with 7.5 μM STLC for 16 h. Cells in the continuous presence of STLC were exposed to 100 μM roscovitine (ROS), 20 μM MG132, both roscovitine and 
MG132, both roscovitine and 0.5 μM okadaic acid (OKAD), or both roscovitine and 30 nM calyculin A (CALYC). Samples for 2D FACScan analysis were 
taken 2 h after the collection of mitotic cells by shake-off. Percentages shown indicate the subpopulations that were positive for MPM-2. Parallel results were 
obtained with nocodazole-treated cells. (C) Comparison of results with nocodazole or with STLC block. Quantitation of the percentage of cells positive for 
MPM2 includes results as shown in B plus a parallel set of data from nocodazole-arrested cells that were otherwise treated identically. Data demonstrate that 
parallel results were obtained with nocodazole or STLC-treated cells. (D) Chromosome spreads 2 h after collection by arrest with nocodazole followed by 
  mitotic shake-off as described in A. Cells were maintained in nocodazole and exposed to various conditions after shake-off as indicated. Bar, 19.36 μm.JCB • VOLUME 179 • NUMBER 4 • 2007  682
would confi  rm that mitotic exit had indeed occurred in the ab-
sence of Cdk1 activity combined with the suppression of prote-
olysis were not examined except phosphorylated nucleolin.
Potapova et al. (2006) suggested that mitotic exit occurred 
with some Cdk1 inhibitors such as purvalanol A but not with 
roscovitine. Importantly, our results have been obtained with 
three different Cdk inhibitors and with two different proteasome 
inhibitors, eliminating the possibility that the capacity to remain 
in mitosis in the absence of Cdk1 activity is dependent on a par-
ticular drug combination.
In accord with Potapova et al. (2006), we fi  nd that a por-
tion of blocked monoastral cells undergo transient furrowing. 
This furrowing is accompanied by the relocation of proteins im-
portant to cytokinesis, such as the passenger proteins Aurora B, 
survivin, and TD60, and of PRC1 to the cell cortex along a 
bundle of microtubules. As a result, these cells form a bud that 
contains no chromatin. Such furrowing is quite similar to that 
previously shown to occur in cells with monoastral spindles in 
which the metaphase checkpoint had been suppressed by the in-
troduction of mutant Mad2 (Canman et al., 2003). These results 
and previous work (Martineau et al., 1995; Wheatley et al., 
1997; Stemmann et al., 2001; Niiya et al., 2005) indicate that 
cytokinesis is an event that is independent of, and neither syn-
chronous nor synonymous with, mitotic exit. Furrowing can 
occur well after mitotic exit has occurred or, as in the case 
presented here, can occur in the absence of mitotic exit. However, 
induction to undergo furrowing may depend on the absence of 
Cdk1 activity.
Cells released from STLC arrest in the presence of MG132 
proceed to metaphase and maintain a bipolar metaphase spindle 
for at least an additional 2 h after the suppression of Cdk1 activ-
ity by roscovitine. The absence of Cdk1 activity clearly does 
not, of itself, drive cells forward from metaphase to anaphase. 
It is of interest that a substantial percentage of cells revert from 
metaphase to prometaphase when Cdk1 activity is suppressed 
in MG132-treated cells (Fig. S2), whereas none are driven for-
ward to anaphase. When chromosomes are lost from the meta-
phase plate, they appear to have a merotelic (both kinetochores 
associated with one spindle pole) kinetochore alignment (un-
published data). Therefore, it appears that continuous Cdk1 ac-
tivity is required to maintain proper metaphase chromosome 
alignment. This apparently unique role for Cdk1 activity in main-
taining bipolar kinetochore attachment has not been noted before 
and deserves attention.
Retention of cells in mitosis is not caused by the contin-
ued presence of either cyclin B1 or securin in the absence 
of Cdk1 activity, as nondegradable mutants of these proteins 
do not prevent mitotic exit in the absence of Cdk1 activity. 
As MG132 nonetheless prevents mitotic exit, the reasonable 
conclusion is that a protease substrate other than cyclin B1 or 
securin must be degraded to permit mitotic exit in the absence 
of Cdk1 activity. Two proteins other than cyclin B1 and securin 
must be degraded for mitosis to progress, but these proteins, cy-
clin A (den Elzen and Pines, 2001; Geley et al., 2001) and Emi1 
(Guardavaccaro et al., 2003; Margottin-Goguet et al., 2003), are 
both eliminated very early in mitosis and are unlikely to play a 
role in mitotic exit.
The putative protease substrate must be involved in phos-
phatase activation. Cdk1 substrates remain substantially phos-
phorylated for hours in the combined presence of different Cdk 
and proteasome inhibitors, and we obtain parallel results on 
  exposing cells to the combination of roscovitine with protein 
phosphatase inhibitors (okadaic acid or calyculin A).
Suppression of the PP1 and PP2A protein phosphatase 
families is required for entry into mitosis (Cyert and Thorner, 
1989; Dohadwala et al., 1994; Wera and Hemmings, 1995; 
Kwon et al., 1997; Puntoni and Villa-Moruzzi, 1997), and both 
okadaic acid and calyculin A specifi  cally inhibit the PP1 and 
PP2A protein phosphatase families (Ishihara et al., 1989). Rea-
sonable candidates for control of mitotic exit are members of 
the PP1 family, as they remain suppressed in mammalian cells 
by phosphorylation until metaphase and can be prolonged in 
this suppressed state by exposure of mitotic cells to either okadaic 
acid or calyculin A (Kwon et al., 1997). Furthermore, micro-
injection of anti-PP1 antibody arrests mammalian cells at meta-
phase (Fernandez et al., 1992). Similarly, the two PP1 proteins 
in Schizosaccharomyces pombe are suppressed by cdc2 phos-
phorylation in mitosis, and their reactivation is required to 
proceed past metaphase (Ishii et al., 1996). PP1 activity is also 
required for mitotic exit in Aspergillus (Doonan and Morris, 
1989) and Drosophila (Axton et al., 1990; Chen et al., 2007).
Our results with the combination of roscovitine and the 
phosphatase inhibitors okadaic acid or calyculin A indicate that 
phosphatase activity is required for exit from the mitotic state, 
presumably by the dephosphorylation of mitotic Cdk1 sub-
strates, and, importantly, that there is little phosphatase activity 
evident on Cdk1 substrates in the presence of roscovitine and 
MG132. The continuing mitotic state, which is characterized by 
condensed chromosomes and by the presence of MPM-2 and 
S10-phosphorylated histone H3 markers, indicates that the 
phosphatase activity required for mitotic exit is minimal when 
APC/C-dependent proteolysis has been suppressed by MG132. 
The potential role of protease inhibition in the suppression of 
phosphatase-dependent mitotic exit is of substantial interest.
The key phosphatase activity must be downstream of 
the cdc20-driven APC/C-dependent protease activity, as cells 
treated with phosphatase inhibitors in the presence of roscovi-
tine have lost both cyclin B1 and securin (Fig. 8) but remain 
metabolically mitotic through the absence of the phosphatase-
dependent destruction of Cdk1 substrates.
In light of a potential key role for protein phosphatases in 
mitotic exit, it is important to note that both budding and fi  ssion 
yeast contain mitotic exit networks that are dependent on unique 
protein phosphatases of the cdc14 family (Visintin et al., 1998; 
Trautmann and McCollum, 2002; Stegmeier and Amon, 2004). 
Although mammalian cdc14A and B are functional homologues 
of cdc14 phosphatases in the yeast system (Vazquez-Novelle 
et al., 2005), suppression of cdc14A in mammalian cells does 
not prevent mitotic exit (Mailand et al.,  2002). We do not be-
lieve that the cdc14 mechanism is likely to play an equivalent 
role in the pathway we describe here, as S. pombe cdc14 (Clp1/
Flp1) directly inactivates cdc2 (the S. pombe homologue of 
Cdk1) by regulating its phosphorylation status. In this scenario, 
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status in the absence of Cdk1 activity. In light of our results with 
combined Cdk and phosphatase inhibitors, it is interesting that 
in Saccharomyces cerevisiae, Cdk activity is required to  activate 
Net1 and, thus, cdc14 in the mitotic exit pathway and that this 
overrides PP2A-dependent metaphase arrest (Queralt et al., 
2006). It will be of substantial interest if a parallel exists be-
tween our results and the yeast pathway that uses Cdk activity 
and phosphatase activation for mitotic exit.
Our results strongly implicate phosphatase activity in key 
events in mitotic exit and protease in activating this pathway. 
Although it remains to be seen whether these effects directly or 
indirectly involve cdc14, it is nonetheless of great interest that 
there appears to be a convergence between the yeast systems 
and the mammalian system in the functional requirement for ac-
tivation of protein phosphatase activity to enable mitotic exit.
In summary, we fi  nd that cells without Cdk1 activity re-
main mitotic by several criteria as long as there is no APC/C-
dependent protease activity and that this effect is dependent on 
mitotic suppression of a key protein phosphatase activity. It will 
now be of great interest to elucidate this important pathway, to 
determine the protease substrate that is retaining these cells in 
mitosis, and to identify the protein phosphatase whose activa-
tion is apparently required for mitotic exit.
Materials and methods
Cell culture
HeLa cells were grown in DME (Invitrogen) supplemented with 10% FCS 
and were maintained in a humid incubator in a 5% CO2 environment at 
37°C. Mitotic cells were collected by shake-off after 16-h incubation with 
either 0.1 μg/ml nocodazole (Sigma-Aldrich) or with 7.5 μM STLC (Nova-
biochem). After centrifugation at 1,000 rpm for 5 min at 37°C, cells were 
resuspended in media in the continuous presence of the mitotic inhibitors 
with either 100 μM roscovitine (Calbiochem) or a combination of roscovi-
tine with 20 μM MG132 (Sigma-Aldrich), or cells were resuspended with 
0.5 μM okadaic acid (Calbiochem) or 30 nM calyculin A (Calbiochem) for 
up to 2 h. Alternatively, mitotic cells were resuspended in media in the con-
tinuous presence of the mitotic inhibitors with either 7.5 μM CGP74514A 
(Calbiochem) or 25 μM purvalanol A (Calbiochem) or with the combina-
tion of CGP74514A or purvalanol A with either 20 μM MG132 (Sigma-
Aldrich) or AM114 (Calbiochem) for up to 2 h. In experiments using 
CGP74514A or purvalanol A, proteasome inhibitors were added 1 h before 
addition of the Cdk inhibitors.
HeLa cells were transfected with either wild-type cyclin B1-GFP or 
the nondegradable (R42A)-cyclin B1-GFP in pCMX vector (gifts from J. 
Pines, Gurdon Institute, Cambridge, UK) or were transfected with the wild-
type myc-securin or nondegradable securin mutant myc-securin-KAA-DM in 
pCS2 vector (gifts from M. Brandeis, Hebrew University, Jerusalem, Israel). 
Double transfection of the nondegradable (R42A)-cyclin B1-GFP and the 
nondegradable securin mutant myc-securin-KAA-D was also performed. 
Single or double plasmid transfections were performed with LipofectAMINE 
(Invitrogen) according to the manufacturer’s protocols. Cells were blocked 
in mitosis with nocodazole at 30 h after transfection and treated with the 
various inhibitors as described in the paragraph above.
Flow cytometric analysis
Cells were analyzed by 2D ﬂ  ow cytometry using MPM-2 monoclonal anti-
body recognizing mitosis-speciﬁ   c phosphoepitopes (Davis et al., 1983) 
and propidium iodide, a marker of DNA content. Cells were ﬁ  xed, incu-
bated with MPM-2 antibodies, and labeled with FITC-conjugated anti–
mouse IgG secondary antibodies (Jackson ImmunoResearch Laboratories) 
and propidium iodide as described previously (Andreassen et al., 2004). 
Data were collected with a ﬂ  ow cytometer (FACScan; Becton Dickinson) 
using propidium iodide in the ﬁ  rst dimension and MPM-2 in the second di-
mension (presented as a dot plot) and were analyzed with CellQuest soft-
ware (Becton Dickinson). For each sample, 10,000 events were collected, 
and aggregated cells were gated out.
Immunoﬂ  uorescence microscopy
Mitotic cells were ﬁ  xed with 2% PFA in PBS for 20 min at 37°C, permeabi-
lized with 0.2% Triton X-100 in PBS for 3 min, stained in suspension, and 
spun onto coverslips at 215 g for 3 min. The following antibodies were 
used for indirect immunoﬂ  uorescence microscopy. Monoclonal antibody to 
β tubulin (Sigma-Aldrich) was used at a 300-fold dilution, MPM-2 mouse 
monoclonal antibody (Upstate Biotechnology) was used at 1:100, and 
  Aurora B was detected with a rabbit polyclonal antibody (Abcam) at a 
500-fold dilution. PRC1 afﬁ  nity-puriﬁ  ed rabbit antibody (gift from W. Jiang, 
Burnham Institute of Medial Research, La Jolla, CA; Jiang et al., 1998), JH 
human autoimmune serum recognizing human TD60 (Andreassen et al., 
1991), and rabbit polyclonal antisurvivin (Novus Biological) were all used 
at 500-fold dilutions. Goat anti–lamin B (Santa Cruz Biotechnology, Inc.) 
was used at a 300-fold dilution. Rabbit polyclonal antibody to anillin 
(gift from C. Field, Harvard University, Cambridge, MA) was used at a 
600-fold dilution. Secondary antibodies (Jackson ImmunoResearch Lab-
oratories), including FITC-conjugated afﬁ  nity-puriﬁ  ed goat anti–mouse, 
anti–rabbit, and rabbit anti–goat IgG antibodies, were used at 1:250; 
Cy3-conjugated afﬁ  nity-puriﬁ  ed goat anti–mouse was used at 1:400. DNA 
was detected by incubation with 0.2 μg/ml propidium iodide in PBS for 
5 min after incubation with secondary antibodies. Samples were observed 
using a microscope (Optiphot; Nikon) coupled to a laser-scanning confo-
cal apparatus (MRC-600; Bio-Rad Laboratories) using the image acquisi-
tion software COMOS (Bio-Rad Laboratories); scans were obtained using 
a 40× NA 1.0 oil objective (Nikon). Treated cells, which were transfected 
with the nondegradable (R42A)-cyclin B1-GFP, were ﬁ  xed and stained in 
the same manner as the above samples and were ﬁ  nally stained with DAPI 
with Vectashield mounting medium (Vector Laboratories). Images were 
  acquired with an epiﬂ  uorescence microscope (BX61; Olympus) equipped 
with a CCD camera (Retiga-SRV; QImaging) driven by Volocity software 
(Improvision) with a binning of 2 using a planApo 60× NA 1.42 objective 
(Olympus). Figures were processed in Photoshop version 7.0 (Adobe) and 
assembled in CANVAS version 8.0 (Denaba Systems).
Cdk1 kinase assay
Kinase assays were performed as described previously (Andreassen and 
Margolis, 1994). In brief, HeLa cells were treated with 0.2 μg/ml no-
codazole for 16 h, and mitotic cells were collected by shake-off, washed 
once with PBS, and lysed in ice-cold buffer C as described previously 
(Panopoulos et al., 2005) containing fresh protease inhibitors (2 μg/ml 
leupeptin, 20 μg/ml aprotinin, 2 μg/ml pepstatin, and 1 mM PMSF), 
phosphatase inhibitor (1.3 mM p-nitrophenyl phosphate), and 2 mM DTT. 
Mouse monoclonal anti-Cdk1 antibody (Abcam) was incubated on ice with 
mitotic lysate (2 μl/100 μg protein) for 30 min before the addition of pro-
tein A–Sepharose beads (Zymed Laboratories). After the addition of beads, 
the lysates were incubated for 5 h at 4°C, rotating end over end. Immune 
complexes were washed once with 600 μl buffer C and twice with kinase 
assay buffer (20 mM Tris, pH 7.6, and 20 mM MgCl2). A master kinase 
cocktail mix was prepared containing kinase assay buffer, 1 μg/ml histone 
H1, 0.2 μCi/μl γ-[
32P]ATP, 30 μM ATP (VWR), and 1 μM DTT. Master 
  kinase cocktail was added to separate tubes containing water (vehicle), 
purvalanol A (25 μM ﬁ  nal), roscovitine (100 μM ﬁ  nal), MG132 (25 μM 
ﬁ  nal), purvalanol A and MG132 (25 μM ﬁ  nal each), or roscovitine and 
MG132 (100 μM ﬁ  nal and 25 μM ﬁ  nal, respectively). For immunoblots, 
immunoprecipitated Cdk1 complexes were resolved by SDS PAGE, trans-
ferred to polyvinylidene diﬂ   uoride membranes, blocked with 5% nonfat 
milk, and probed with anti-Cdk1 antibody (1:500 dilution; Abcam).
Chromosome spreads
To prepare chromosome spreads, cells in suspension were pelleted by cen-
trifugation at 215 g for 2 min and were resuspended in 75 mM KCl at 
37°C for 30 min. Cells were then centrifuged again (2 min at 215 g) and 
ﬁ  xed overnight at –20°C in 75% methanol and 25% acetic acid. Spreads 
were then obtained by resuspension of ﬁ  xed cells and centrifugation onto 
coverslips (Cytospin centrifuge; Thermo Scientiﬁ  c) at 2,800 rpm for 3 min. 
The chromosome spread was then washed with PBS, stained for 5 min with 
0.5 μg/ml propidium iodide in PBS, washed again twice, and mounted 
for observation.
Immunoblotting
Cells were lysed in 50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 5 mM EGTA, 
and 0.1% NP-40 and were supplemented with protease and phosphatase 
inhibitors for 30 min on ice. 20 μg of lysates was resolved on polyacryl-
amide gels and transferred to nitrocellulose sheets. Materials are listed with 
their dilutions as follows: β tubulin was detected with a mouse anti–β tubulin JCB • VOLUME 179 • NUMBER 4 • 2007  684
monoclonal antibody (Sigma-Aldrich), 1:1,000; mouse anti–cyclin B1 
monoclonal antibody (clone GNS1; Santa Cruz Biotechnology, Inc.), 
2,000-fold dilution; rabbit polyclonal anti–Aurora A (Cell Signaling), 
1,000-fold dilution; polyclonal antisecurin antibody (gift from H. Zou, 
  University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Zou 
et al., 1999), 500-fold dilution; polyclonal antiactin, 10,000-fold dilution 
(Sigma-Aldrich); rabbit antiphospho-S10 H3 (Upstate Biotechnology), 
5,000-fold dilution; mouse monoclonal anti-myc (clone 9E10; Santa Cruz 
Biotechnology, Inc.), 1,000-fold dilution; rabbit antiphospho-(serine)-CDK 
substrate antibody (Cell Signaling), 1,000-fold dilution; and rabbit anti-
phospho-(T244)-cdc27 antibody (Abcam), 1,000-fold dilution. Nitrocellu-
lose sheets were then incubated with HRP-conjugated goat anti–mouse and 
anti–rabbit IgG secondary antibodies. Protein–antibody complex was de-
tected by enhanced chemiluminescence (Pierce Chemical Co.).
Online supplemental material
Fig. S1 shows that nontransformed cells are retained in mitosis after loss of 
Cdk activity when proteasome activity is also suppressed. Fig. S2 shows 
that the absence of Cdk1 activity permits bipolar spindle formation and 
metaphase chromosome alignment on release from STLC, but many cells 
revert to prometaphase. Fig. S3 shows that cdc25 phosphatase activity has 
no effect on mitotic exit. Fig. S4 shows quantitation of treated cells for chro-
mosomes versus interphase nuclei. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200704117/DC1.
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